Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/9/?d=1Neue Studien: Europe PMCdeManagement of Obesity in Psoriasis Consultations.https://www.psoriasis-news.de/articles.html/1_articles/management-of-obesity-in-psoriasis-consultations-r443/IntroductionPsoriasis and obesity often occur together, with up to 50% of patients with psoriasis being classified as obese. This increases systemic inflammation, cardiovascular risk, and disease severity while reducing the efficacy of biologic treatments. Despite this overlap, dermatology lacks obesity-specific guidance. This review evaluates lifestyle, pharmacological (glucagon-like peptide 1 receptor agonists [GLP-1 RAs] and tirzepatide) and surgical strategies, as well as clinic-level algorithms, to inform dermatological practice.

Methods

We performed a narrative synthesis of epidemiology, randomized trials, real-world studies, and guideline recommendations. Our focus was on the pathophysiology and the efficacy of GLP-1 RAs and tirzepatide, providing a practical algorithm pathway for triage, pharmacotherapy escalation, and referral criteria to a multidisciplinary unit.

Results

Although there are no psoriasis-specific guidelines for obesity treatment, the strong link between the two conditions and the poorer therapeutic response observed in obese patients make addressing excess weight essential for people with psoriasis. The proposed algorithms emphasize universal lifestyle counseling and dermatology-led management for patients with a BMI (body mass index) < 35 kg/m2 and without major metabolic complications. GLP-1 RAs are considered the first-line treatment, given the available scientific evidence about their efficacy in terms of weight loss and management of comorbidities, as well as their safety profile. If weight loss with these drugs is insufficient, the next proposed treatment step is tirzepatide. Bariatric surgery, including bypass procedures, should be reserved for patients with a BMI ≥ 40 kg/m2, or with a BMI ≥ 35 kg/m2 when earlier measures have failed and/or comorbidities are not adequately controlled.

Conclusion

Dermatologists should integrate obesity assessment and patient-centered interventions into psoriasis care. A structured, multidisciplinary approach could meaningfully enhance dermatological, metabolic, and cardiovascular outcomes in patients with psoriasis and obesity.

Weiterlesen

]]>443Tue, 10 Feb 2026 08:00:25 +0000Erectile dysfunction and associated factors in males with psoriasis: a case-control study.https://www.psoriasis-news.de/articles.html/1_articles/erectile-dysfunction-and-associated-factors-in-males-with-psoriasis-a-case-control-study-r442/Weiterlesen

]]>442Tue, 10 Feb 2026 08:00:25 +0000Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report.https://www.psoriasis-news.de/articles.html/1_articles/infliximab-induced-paradoxical-psoriasis-successfully-treated-with-secukinumab-a-case-report-r441/Weiterlesen

]]>441Tue, 10 Feb 2026 08:00:25 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situationshttps://www.psoriasis-news.de/articles.html/1_articles/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r440/No abstract supplied.

Weiterlesen

]]>440Tue, 10 Feb 2026 08:00:25 +0000Differences in the Expression of Insulin-Like Growth Factor Signaling Pathway Members in Patients With Psoriasis Vulgaris and Controls.https://www.psoriasis-news.de/articles.html/1_articles/differences-in-the-expression-of-insulin-like-growth-factor-signaling-pathway-members-in-patients-with-psoriasis-vulgaris-and-controls-r439/Weiterlesen

]]>439Tue, 10 Feb 2026 08:00:25 +0000Advancements in psoriasis classification using custom transfer learning algorithms.https://www.psoriasis-news.de/articles.html/1_articles/advancements-in-psoriasis-classification-using-custom-transfer-learning-algorithms-r438/Weiterlesen

]]>438Tue, 10 Feb 2026 08:00:25 +0000Delayed Diagnosis of Psoriatic Arthritis Presenting with Infection-like Finger Inflammation: A Case Report.https://www.psoriasis-news.de/articles.html/1_articles/delayed-diagnosis-of-psoriatic-arthritis-presenting-with-infection-like-finger-inflammation-a-case-report-r437/Weiterlesen

]]>437Tue, 10 Feb 2026 08:00:25 +0000Single-cell transcriptomics reveals keratinocyte dynamic processes associated with S100a4 expression in psoriasiform dermatitishttps://www.psoriasis-news.de/articles.html/1_articles/single-cell-transcriptomics-reveals-keratinocyte-dynamic-processes-associated-with-s100a4-expression-in-psoriasiform-dermatitis-r436/No abstract supplied.

Weiterlesen

]]>436Tue, 10 Feb 2026 08:00:25 +0000Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity.https://www.psoriasis-news.de/articles.html/1_articles/transcriptomic-profiling-and-machine-learning-uncover-gene-signatures-of-psoriasis-endotypes-and-disease-severity-r434/BackgroundDespite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments.

Methods

We performed comprehensive RNA sequencing of skin and blood (n = 718) from prospectively-recruited, deeply-phenotyped discovery and replication cohorts of 146 subjects with moderate-to-severe chronic plaque psoriasis initiating TNF-inhibitor (adalimumab) or IL-12/23-inhibitor (ustekinumab) therapy.

Results

Here we show, using two complementary dimensionality reduction methods, that co-expressed gene modules and factors within skin and blood are significantly associated with psoriasis phenotypes and disease severity. We identify a 14-gene signature negatively associated with BMI in nonlesional skin and with disease severity in lesional skin. Genotype integration reveals that HLA-DQA1*01 and HLA-DRB1*15 genotypes are positively associated with baseline psoriasis severity. Using explainable machine learning models, we define two disease severity-associated gene modules in lesional skin - one positive, one negatively-associated - and a 9-gene signature in lesional skin predictive of disease severity. Disease severity signatures in blood are only seen following adalimumab exposure, suggesting greater systemic impact of adalimumab compared to ustekinumab, in line with its side effect profile. In contrast, a gene signature in blood linked to HLA-C*06:02 status is independent of disease severity or drug.

Conclusions

These findings delineate gene-environmental and genetic effects on the psoriasis transcriptome linked to disease severity.

Weiterlesen

]]>434Tue, 03 Feb 2026 08:49:23 +0000Accuracy Assessment of Chinese Large Language Models in Psoriasis Management: A Multicenter Expert Consensus Studyhttps://www.psoriasis-news.de/articles.html/1_articles/accuracy-assessment-of-chinese-large-language-models-in-psoriasis-management-a-multicenter-expert-consensus-study-r433/Background Psoriasis patients in China face significant challenges due to insufficient disease knowledge and limited access to medical resources, creating a need for reliable educational tools. Objectives This multicenter consensus study aimed to systematically evaluate the consultation quality of mainstream Chinese large language models (LLMs) for psoriasis patient education. Methods "365 Questions on Psoriasis" was jointly compiled by 109 Chinese psoriasis experts. Using an expert assessment methodology, nine dermatologists curated 40 high-frequency clinical questions from the book across five domains (etiology, triggers, treatment, management, psychosocial impact). Four Chinese LLMs (DeepSeek-R1, DeepSeek-V3, GLM-4, Qwen-3) were evaluated through double-blind scoring on a 10-point Likert scale assessing accuracy, completeness, clarity, and safety. Results Performance varied significantly, with mean scores ranging from 5.95 to 9.88 (SD: 0-3.05). Qwen-3 achieved the highest average score (9.12), while GLM-4 showed the greatest inconsistency. All responses avoided dangerous content, and 87.5% proactively emphasized the necessity of consulting a physician. However, 12.5% of responses deviated from evidence-based guidelines, particularly on complex topics like biologics and management. Conclusions Chinese LLMs show substantial potential for psoriasis education by providing generally safe information and appropriately directing users to doctors. However, current limitations exist, including performance inconsistency and occasional deviations from guidelines on specialized topics, indicating they are not yet replacements for professional medical.

Weiterlesen

]]>433Tue, 03 Feb 2026 08:49:23 +0000Therapeutic approach with fatty acids in psoriasis: A systematic review.https://www.psoriasis-news.de/articles.html/1_articles/therapeutic-approach-with-fatty-acids-in-psoriasis-a-systematic-review-r432/ObjectiveThis study aims to evaluate the clinical impacts of topical and/or oral administration of compounds rich in omega-3 fatty acids from various sources, such as oils and foods, on psoriatic lesions.

Design

A systematic review was carried out.

Data sources

Searches were conducted in six databases (PubMed, Cochrane, VHL, Scopus, Embase, and Web of Science) using descriptors related to fatty acids and psoriasis.

Study selection

Inclusion criteria were studies published in the last 10 years (2013-2023) that involved patients with psoriasis and provided quantitative clinical outcome data, such as psoriasis severity scale.

Data extraction

Two independent reviewers carried out the initial screening of the titles and abstracts identified in the search. The quality of studies was evaluated using the Newcastle-Ottawa Scale, the Risk of Bias in Randomized Studies of Interventions, and the Joanna Briggs Institute critical appraisal checklist.

Results

Out of 8570 articles identified, 9 met the inclusion criteria. The quality of randomized clinical trials and observational studies varied from low to high risk of bias, according to the respective parameters of each checklist.

Conclusions

Most studies demonstrated that the topical and/or oral administration of omega-3 fatty acids from different sources significantly improved clinical parameters, as measured by severity scales and the Psoriasis Area and Severity Index (PASI).

Weiterlesen

]]>432Tue, 03 Feb 2026 08:49:23 +0000In vivo multiphoton microscopy of psoriasis: A new diagnosis and therapeutic monitoring technique.https://www.psoriasis-news.de/articles.html/1_articles/in-vivo-multiphoton-microscopy-of-psoriasis-a-new-diagnosis-and-therapeutic-monitoring-technique-r431/Background and objectivesPsoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.

Patients and methods

This prospective observational study enrolled 34 patients with psoriasis. It comprised three parts: (1) analysis of imaging features of lesional and nonlesional skin using multiphoton microscopy (MPM; Transcend Vivoscope); (2) evaluation of the diagnostic performance of MPM parameters compared with reflectance confocal microscopy (RCM); and (3) prospective monitoring of 24 patients treated with Benvitimod (Tapinarof) cream for 8 weeks (T0/T1/T2).

Results

MPM detected psoriasis characteristics (including hyperkeratosis, parakeratosis, an absent stratum granulosum, enlarged nucleus diameter, and absent bright rimming) with comparable diagnostic efficiency to RCM (AUC = 0.838, p < 0.001 vs. 0.824, p < 0.001). Psoriatic lesions showed significant perinuclear fluorescence accumulation compared to healthy skin (p < 0.001). All imaging features improved significantly after 8 weeks of treatment (p < 0.001). PASI/TLS scores showed correlations with the epidermal thickness (r = 0.403/0.492, p < 0.001), nuclear diameter (r = 0.4/0.375, p < 0.001), and fluorescence intensity (r = -0.419/-0.492, p < 0.001).

Conclusions

MPM is a novel and non-invasive imaging technique for psoriasis evaluation and treatment monitoring.

Weiterlesen

]]>431Tue, 03 Feb 2026 08:49:23 +0000Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/clinical-proof-of-concept-for-small-molecule-mediated-inhibition-of-il-17-in-psoriasis-r430/Weiterlesen

]]>430Tue, 03 Feb 2026 08:49:23 +0000Early maladaptive schemas, emotion regulation, coping with stress, quality of life, and psychological symptoms in psoriasis disease.https://www.psoriasis-news.de/articles.html/1_articles/early-maladaptive-schemas-emotion-regulation-coping-with-stress-quality-of-life-and-psychological-symptoms-in-psoriasis-disease-r429/2 = .46). Findings suggest maladaptive emotion-focused coping as a key mechanism linking schemas to psoriasis outcomes, supporting integrated dermatological and psychological interventions.

Weiterlesen

]]>429Tue, 03 Feb 2026 08:49:23 +0000The path to interception in psoriatic disease: from conceptual clarity to clinical translation.https://www.psoriasis-news.de/articles.html/1_articles/the-path-to-interception-in-psoriatic-disease-from-conceptual-clarity-to-clinical-translation-r428/Weiterlesen

]]>428Tue, 03 Feb 2026 08:49:23 +0000Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/systemic-treatment-strategies-for-patients-with-psoriasis-and-psoriatic-arthritis-in-the-setting-of-ana-positivity-or-lupus-spectrum-disease-a-comprehensive-systematic-review-r427/Weiterlesen

]]>427Tue, 03 Feb 2026 08:49:23 +0000Differential clinical factors influencing the effectiveness of distinct biologic agents in psoriasis: insights from a prospective cohort study in China.https://www.psoriasis-news.de/articles.html/1_articles/differential-clinical-factors-influencing-the-effectiveness-of-distinct-biologic-agents-in-psoriasis-insights-from-a-prospective-cohort-study-in-china-r426/Objective and designThis prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.

Subjects

Patients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.

Treatment

Guideline-recommended dosing; 3-month follow-up.

Methods

The primary endpoint was PASI90 response at 3 months. Multivariable logistic regression estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for clinical predictors of treatment response.

Results

A total of 717 patients were included in the analysis. In guselkumab-treated patients, obesity (aOR 0.22, 95% CI 0.06-0.78) and prior biologic exposure (aOR 0.22, 95% CI 0.06-0.75) were independently associated with reduced PASI90 response. Psoriatic arthritis predicted poorer response to ustekinumab (aOR 0.16, 95% CI 0.03-0.78). For secukinumab, male sex reduced the likelihood of PASI90 (aOR 0.47, 95% CI 0.23-0.96), whereas family history of psoriasis improved outcomes (aOR 2.20, 95% CI 1.10-4.42). In ixekizumab-treated patients, obesity (aOR 0.38, 95% CI 0.18-0.80) was a negative predictor, while family history (aOR 2.79, 95% CI 1.22-6.38) enhanced treatment response.

Conclusions

Predictors of biologic effectiveness differ by agent, supporting personalized treatment based on patient characteristics.

Weiterlesen

]]>426Tue, 03 Feb 2026 08:49:23 +0000Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trialhttps://www.psoriasis-news.de/articles.html/1_articles/impact-of-treatment-interruption-on-the-efficacy-and-safety-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-a-post-hoc-analysis-of-a-phase-3-trial-r425/No abstract supplied.

Weiterlesen

]]>425Tue, 03 Feb 2026 08:49:23 +0000Do Nails Tell a Pulmonary Tale? A Cross-Sectional Study on Psoriasis and Pulmonary Hypertension Risk.https://www.psoriasis-news.de/articles.html/1_articles/do-nails-tell-a-pulmonary-tale-a-cross-sectional-study-on-psoriasis-and-pulmonary-hypertension-risk-r416/BackgroundPsoriasis is a systemic inflammatory disease associated with cardiopulmonary comorbidities. Nail psoriasis, quantified by the Nail Psoriasis Severity Index (NAPSI), is a marker of severe disease. While pulmonary arterial hypertension (PAH) is reported more frequently in psoriasis, the specific correlation between nail psoriasis severity and PAH remains underexplored.

Objective

To investigate the correlation between NAPSI scores and the presence or severity of PAH in patients with psoriasis.

Methods

A prospective, cross-sectional study was conducted at a tertiary care centre involving 100 patients with chronic plaque psoriasis (50 with and 50 without nail psoriasis). All participants underwent dermatological evaluation [Psoriasis Area and Severity Index (PASI) and NAPSI scoring], transthoracic echocardiography to estimate pulmonary artery systolic pressure (PASP), and measurement of inflammatory markers [C-reactive protein (CRP), IL-17, TNF-α]. PAH was defined as PASP > 35 mmHg. Statistical analyses included correlation tests, comparative analyses, and multivariate logistic regression.

Results

PAH was identified in 29% (n = 29) of patients, with a significantly higher prevalence in the nail psoriasis group (40% vs 18%, P = .01). Patients with PAH had higher mean NAPSI scores than those without (29.5 ± 13.4 vs 18.2 ± 10.6, P = .001). A moderate positive correlation was found between NAPSI scores and PASP (r = 0.44, P < .001). PASI scores and CRP levels were also significantly elevated in patients with PAH and correlated with PASP (r = 0.38, P = .001 and r = 0.41, P < .001, respectively).Multivariate analysis confirmed NAPSI score as an independent predictor of PAH [odds ratio (OR): 1.07/unit increase, 95% CI: 1.03-1.11, P = .002], after adjusting for confounders including PASI score and comorbidities. PASI (OR: 1.05, P = .01) and CRP (OR: 1.13, P = .008) were also independent predictors. Nail matrix involvement was more strongly associated with PAH than nail bed involvement (P = .03). Inflammatory markers (CRP, IL-17, TNF-α) were significantly elevated in patients with PAH.

Conclusion

NAPSI scores, PASI scores, and CRP levels are all significantly correlated with and independently predict PAH in patients with psoriasis. Assessment of nail psoriasis severity may serve as a valuable, noninvasive clinical tool to identify psoriasis patients at increased risk of pulmonary vascular complications, warranting further cardiological evaluation.

Weiterlesen

]]>416Sun, 25 Jan 2026 18:42:10 +0000Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results from the German Psoriasis Registry PsoBest.https://www.psoriasis-news.de/articles.html/1_articles/outcomes-in-patients-with-psoriasis-following-apremilast-treatment-results-from-the-german-psoriasis-registry-psobest-r415/IntroductionThe German national psoriasis registry PsoBest collects long-term data on the effectiveness, safety, and tolerability of systemic treatments for psoriatic disease. Here, we describe patient characteristics and the safety and effectiveness of apremilast for the treatment of psoriatic disease in Germany based on data from PsoBest.

Methods

This was a descriptive analysis of observational data collected from PsoBest using cross-sectional (baseline characteristics) and longitudinal (outcomes, safety) designs. PsoBest recruits patients with moderate to severe plaque psoriasis or psoriatic arthritis who initiate a new systemic psoriasis treatment. Adverse events (AEs) and sociodemographic descriptors were reported for patients exposed to apremilast during the study period (safety cohort). Clinical and patient-reported outcomes were collected 3, 6, and 12 months after the initiation of apremilast monotherapy (outcomes cohort).

Results

From January 15, 2015 to June 30, 2020, 595 registry patients were exposed to apremilast; 417 were treated with apremilast monotherapy. Patients taking apremilast had a higher mean age and higher proportions of comorbidities such as cardiovascular or metabolic disease compared with those taking other nonbiologic systemic or biologic drugs. The most common nonserious AEs were drug ineffectiveness (14.1%), diarrhea (9.4%), nausea (7.1%), and headache (6.1%). The highest incidence rates of nonserious and serious AEs of special interest were for infections and infestations per system organ class (8.03/100 patient-years) and malignant or unspecified tumors (2.50/100 patient-years), respectively. Improvements in Dermatology Life Quality Index, patient-defined treatment benefits (Patient Benefit Index), body surface area, and Psoriasis Area and Severity Index were observed after 3, 6, and 12 months of apremilast treatment.

Conclusions

Patients in routine care treated with apremilast in the German PsoBest registry experienced treatment benefits and improved skin, psoriasis severity, and quality of life. Safety was consistent with the established safety profile. Apremilast is safe and effective for treating moderate to severe psoriatic disease.

Weiterlesen

]]>415Sun, 25 Jan 2026 18:42:10 +0000Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.https://www.psoriasis-news.de/articles.html/1_articles/evaluating-risankizumabs-long-term-effects-in-psoriasis-using-optical-coherence-tomography-r414/IntroductionPsoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surface Area (BSA) focus on evaluating visible symptoms and are limited in capturing underlying disease activity. Optical coherence tomography (OCT), a non-invasive imaging modality, offers real-time assessment of structural and vascular changes, providing valuable insights beyond the skin surface.

Methods

This sub-analysis of a prospective, single-center exploratory study included 22 patients with moderate-to-severe psoriasis treated with risankizumab. Clinical assessments (PASI, IGA, BSA) were conducted at baseline and weeks 2, 4, 16, 28, 40, and 52. OCT imaging performed at baseline and weeks 4, 16, and 52 evaluated epidermal thickness and vascular parameters (e.g., vessel density and diameter) in lesional and perilesional skin.

Results

By week 16, mean (95% confidence interval [CI]) PASI score decreased from 16.3 (11.6-21.1) at baseline to 3.5 (1.8-5.2), and BSA involvement from 24.7% (16.1-33.3) to 5.2% (1.9-8.4) (both p < 0.001). By week 52, 86.7%, 73.3%, and 40.0% of patients achieved PASI 75, 90, and 100, respectively, and 93.3% achieved IGA 0/1. OCT showed lesional reductions in epidermal thickness (- 37.4%), vessel density (- 26.6% Δ area under the curve [AUC]), and vessel diameter (- 59.5% ΔAUC) over the 52-week period. Notably, vascular changes also occurred in uninvolved perilesional skin.

Conclusion

Risankizumab improved both clinical and OCT parameters over 52 weeks, emphasizing the importance of long-term therapy with benefits extending beyond visible improvement. OCT emerged as a valuable tool for assessing deep (vascular) treatment response, thereby supporting a more comprehensive understanding of therapeutic outcomes in psoriasis.

Weiterlesen

]]>414Sun, 25 Jan 2026 18:42:10 +0000Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature.https://www.psoriasis-news.de/articles.html/1_articles/dual-biologic-therapy-in-a-patient-with-severe-psoriasis-and-psoriatic-arthritis-using-guselkumab-and-bimekizumab-a-case-report-and-review-of-the-literature-r413/Weiterlesen

]]>413Sun, 25 Jan 2026 18:42:10 +0000Exploration of shared gene signatures and molecular mechanisms between psoriasis and COVID-19: evidence from transcriptome data.https://www.psoriasis-news.de/articles.html/1_articles/exploration-of-shared-gene-signatures-and-molecular-mechanisms-between-psoriasis-and-covid-19-evidence-from-transcriptome-data-r412/No abstract supplied.

Weiterlesen

]]>412Sun, 25 Jan 2026 18:42:10 +0000Psychometric Evaluation of Patients With Atopic Dermatitis and Comparison With Patients With Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/psychometric-evaluation-of-patients-with-atopic-dermatitis-and-comparison-with-patients-with-psoriasis-r411/Atopic dermatitis and psoriasis are two dermatological diseases that affect the mental health of patients. The purpose of this research is to investigate the comparison of the psychometric characteristics of two groups of patients with psoriasis and atopic dermatitis respectively focusing on depression, personality, hostility and psychosomatic burden. Τhe sample was consisted by 100 patients with psoriasis and 40 patients with atopic dermatitis, respectively. Specific questionnaires were given for the psychometric evaluation of patients with atopic dermatitis and psoriasis. The Beck's Depression Inventory (BDI), the Eysenck Personality Questionnaire (EPQ) the Brief Symptom Inventory SCL-90 scale, and the HDHQ questionnaire (Psychometric Hostility and Direction of Hostility Questionnaire). Patients with atopic dermatitis have statistically significantly higher scores on the scale of somatization and paranoid ideation, while patients with psoriasis have statistically significantly higher scores on the scale of depression. On the personality scales, patients with atopic dermatitis have on average statistically significantly higher scores on the psychoticism scale and lower scores on the lying scale than the psoriatic patients. Patients with atopic dermatitis present statistically significantly higher scores on the scale of paranoid hostility than patients with psoriasis. Patients receiving medication as well as the interaction of disease group with receiving medication are statistically significantly related to the psychopathology index. Patients' scores on the psychotic scale of the EPQ are statistically significantly related to the duration of the illness and the patient group, gender and medication intake. The psychosocial effects of psoriasis and atopic dermatitis on patients' mental health are demonstrated in the present study based on patient scores on psychometric scales and psychopathology index.

Weiterlesen

]]>411Sun, 25 Jan 2026 18:42:10 +0000Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/incidence-rate-and-risk-factors-of-arrhythmias-in-patients-with-psoriatic-arthritis-r410/ObjectivesTo assess the incidence and risk factors for arrhythmias in patients with psoriatic arthritis (PsA).

Methods

We performed a cohort analysis of patients followed prospectively from 1994 to 2024. Participants were evaluated using standard protocols at 6-to-12-month intervals. The following events were assessed: (1) atrial tachyarrhythmia (including atrial fibrillation and supraventricular tachycardia); (2) ventricular tachyarrhythmia and (3) bradycardia/pacemaker. The cumulative incidence rate (CIR) of each arrhythmia was calculated. Cox proportional hazards models (reported as the current level HR (measured just prior to the event) and the adjusted mean HR) were fitted to assess the association between selected measures of PsA disease activity and the age of occurrence of arrhythmia events. Each model was adjusted for sex, PsA duration, cardiovascular risk factors and medications.

Results

A total of 1670 patients with PsA were analysed (80 atrial tachyarrhythmias, 17 bradyarrhythmias/pacemakers and 11 ventricular tachyarrhythmias). By age 70, the CIRs were 7.82%, 0.67% and 0.45% for atrial, ventricular and bradycardia, respectively. In multivariable analysis, remission/low versus high disease activity state was associated with lower risk of atrial tachyarrhythmia (current HR 0.49, 95% CI 0.26 to 0.92; adjusted mean HR 0.46, 95% CI 0.23 to 0.91). Similarly, a higher three-item Visual Analogue Scale (3-VAS) was associated with a higher risk of atrial tachyarrhythmia (current level HR 1.18, 95% CI 1.04 to 1.33; adjusted mean HR 1.22, 95% CI 1.04 to 1.44).

Conclusions

Higher PsA disease activity is associated with higher atrial tachyarrhythmia risk. These findings reinforce the importance of controlling inflammation in PsA to optimise cardiac health.

Weiterlesen

]]>410Sun, 25 Jan 2026 18:42:10 +0000